CLEVELAND, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Parker Hannifin Corporation (NYSE:PH), the global leader in motion and control technologies, today reported results for the quarter and year ended June 30, 2024, that included the following highlights (compared with the prior year period): Fiscal 2024 Fourth Quarter Highlights: Sales increased 2% to a record $5.2 billion; Organic sales growth was 3%Net income was $785 million, or $884 million adjustedEPS were $6.01, an increase of 10%, or a record $6.77 adjusted, ...

– Preclinical data suggest combination of ziftomenib and imatinib has potential to resensitize patients to imatinib and induce durable responses – – Proof-of-concept study evaluating ziftomenib and imatinib in patients with advanced GIST to begin in 1H 2025 – SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced clearance by the U.S. Foo ...

Q2 operating earnings of $12.2 million; $28.1 million on an adjusted basis, up 95% Q2 revenue down following sale of European staffing operations; up 0.6% on an organic basis Q2 adjusted EBITDA margin increased 170 basis points to 3.7% driven by meaningful reduction in operating expenses resulting from business transformation initiatives and sale of European staffing operations Company expects further expansion of EBITDA margin from the May 31, 2024 acquisition of Motion Recruitment Partners, LLC ("MRP") TR ...

Phase 2 study of NTLA-2002 for hereditary angioedema (HAE) met its primary and all secondary endpoints; plan to present detailed results at an upcoming medical meeting in the fourth quarterSelected the 50 mg dose of NTLA-2002 for the pivotal Phase 3 trial on track to begin in 2H 2024Rapid enrollment continues in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathyOn track to initiate the Phase 3 study of NTLA-2001 for the treatment of hereditary ...

– Initiation of Phase 1 CALiPSO-1 Trial of CNTY-101 in Systemic Lupus Erythematosus, marking strategic expansion into autoimmune disease; protocol amended to include additional cohort of Lupus Nephritis patients – – Presented interim results from Phase 1 ELiPSE-1 trial of CNTY-101 demonstrating encouraging preliminary efficacy and tolerability data in heavily pretreated relapsed/refractory –   – Completed dose escalation for ELiPSE-1 and advancing into dose expansion in 2H 2024 – – Ended second quarter 2024 ...

Successful clinical translation of Wave's RNA medicines platform in HD patients with WVE-003 provides further validation of Wave's proprietary platform with PN and stereochemistry; opt-in package for WVE-003 submitted to partner Takeda and engagement with regulators initiated to discuss potential path to accelerated approval Dystrophin data on track for 3Q 2024 from potentially registrational FORWARD-53 trial of WVE-N531, which has previously demonstrated industry-leading exon skipping of 53%; positive data ...

SHENZHEN, China, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ:JG) ("Aurora Mobile" or the "Company"), a leading provider of customer engagement and marketing technology services in China, today released a summary of an interview of its Chief Financial Officer, Mr. Shan-Nen Bong with an overseas financial magazine. Interview summary: Interviewer: In the past four quarterly earnings reports, I noticed that your company's gross margin remained between 65% and 72%. This is a fairly high level ...

文章核心观点 - 公司发布了其位于玻利维亚波托西的Silver Sand项目的独立预可行性研究(PFS)技术报告 [1][2] - 该PFS技术报告是根据加拿大证券管理局的国家文书43-101-矿产项目披露标准编制的 [2] - 该PFS技术报告由多名合资格人士编制,包括AMC Mining Consultants、Halyard Inc.和NewFields Canada Mining & Environment ULC等公司的专业人士 [3] - 该技术报告已经过公司勘探副总裁张先生的审核和批准 [4] - 该PFS技术报告可在公司网站、SEDAR+和EDGAR等渠道获取 [5] 公司概况 - 公司是一家加拿大的勘探和开发公司,在玻利维亚拥有三个贵金属项目 [6] - 公司的旗舰项目Silver Sand有潜力成为全球最大的银矿之一 [6] - 公司正在快速推进Carangas项目的初步经济评估,并于2022年完成了Silverstrike项目的发现钻探计划 [6] 前瞻性信息 - 公司对项目的未来开发、勘探、建设等活动做出了前瞻性预测和假设 [9][10][11] - 这些前瞻性信息受到多种风险和不确定因素的影响,可能与实际结果存在差异 [10][11][12] - 公司提醒投资者注意这些风险因素,并表示除法律要求外,公司没有义务更新这些前瞻性信息 [12] 美国投资者警示 - 该新闻稿是根据加拿大证券法编制的,与美国证券法存在差异 [13] - 因此,其中包含的技术和科学信息,包括矿产储量和资源量估算,可能无法与美国公司披露的信息进行比较 [13]

HAIFA, Israel, Aug. 8, 2024 /PRNewswire/ -- Elbit Systems Ltd. (NASDAQ: ESLT) (TASE: ESLT) ("Elbit Systems" or the "Company") announced today that it was awarded a contract worth approximately $130 million to supply Iron Fist Active Protection Systems (APS) to BAE Systems Hägglunds. The systems will be installed on the CV90 Infantry Fighting Vehicle (IFV) as part of a project of a European country. The contract will be performed over a period of five and a half years. The Iron Fist APS is an advanced Hard K ...

Fans of the film can now get their hands on an exclusive collection of products including a Limited-Edition Beetlejuice flavour, with more thrills to come. ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Today, Fanta® and Warner Bros. Pictures are excited to announce a global partnership ahead of the release of the highly anticipated movie Beetlejuice Beetlejuice – debuting in cinemas on September 6th, 2024. Manifesting the spirit of the mischievous demon, Fanta® and Warner Bros. Pictures are coming together to bring ...